306 related articles for article (PubMed ID: 25330750)
1. Targeted therapy in sarcomas other than GIST tumors.
Sborov D; Chen JL
J Surg Oncol; 2015 Apr; 111(5):632-40. PubMed ID: 25330750
[TBL] [Abstract][Full Text] [Related]
2. Dermatofibrosarcoma protuberans and gastrointestinal stromal tumor as models for targeted therapy in soft tissue sarcomas.
Koseła-Paterczyk H; Rutkowski P
Expert Rev Anticancer Ther; 2017 Dec; 17(12):1107-1116. PubMed ID: 28988501
[TBL] [Abstract][Full Text] [Related]
3. Anti-angiogenic therapy, a new player in the field of sarcoma treatment.
Versleijen-Jonkers YM; Vlenterie M; van de Luijtgaarden AC; van der Graaf WT
Crit Rev Oncol Hematol; 2014 Aug; 91(2):172-85. PubMed ID: 24613529
[TBL] [Abstract][Full Text] [Related]
4. Novel treatment targets in sarcoma: more than just the GIST.
Shoushtari AN; Van Tine BA; Schwartz GK
Am Soc Clin Oncol Educ Book; 2014; ():e488-95. PubMed ID: 24857144
[TBL] [Abstract][Full Text] [Related]
5. Molecular diagnostics in soft tissue sarcomas and gastrointestinal stromal tumors.
Smith SM; Coleman J; Bridge JA; Iwenofu OH
J Surg Oncol; 2015 Apr; 111(5):520-31. PubMed ID: 25772665
[TBL] [Abstract][Full Text] [Related]
6. Small bowel sarcoma: Tumor biology and advances in therapeutics.
Shenoy S
Surg Oncol; 2015 Sep; 24(3):136-44. PubMed ID: 26278844
[TBL] [Abstract][Full Text] [Related]
7. Histology-Specific Uses of Tyrosine Kinase Inhibitors in Non-gastrointestinal Stromal Tumor Sarcomas.
Sethi TK; Keedy VL
Curr Treat Options Oncol; 2016 Feb; 17(2):11. PubMed ID: 26931561
[TBL] [Abstract][Full Text] [Related]
8. Targeted treatments of sarcomas and connective tumors beside gastrointestinal stromal tumor.
Martin-Broto J; Hindi N
Curr Opin Oncol; 2016 Jul; 28(4):338-44. PubMed ID: 27166665
[TBL] [Abstract][Full Text] [Related]
9. Novel targeted therapies in the treatment of soft-tissue sarcomas.
Chao J; Chow WA; Somlo G
Expert Rev Anticancer Ther; 2010 Aug; 10(8):1303-11. PubMed ID: 20735315
[TBL] [Abstract][Full Text] [Related]
10. Tyrosine kinase inhibitors in treating soft tissue sarcomas: sunitinib in non-GIST sarcomas.
Homet Moreno B; Garralda Cabanas E; Hitt R
Clin Transl Oncol; 2010 Jul; 12(7):468-72. PubMed ID: 20615823
[TBL] [Abstract][Full Text] [Related]
11. Ethyl-2-amino-pyrrole-3-carboxylates are novel potent anticancer agents that affect tubulin polymerization, induce G2/M cell-cycle arrest, and effectively inhibit soft tissue cancer cell growth in vitro.
Boichuk S; Galembikova A; Zykova S; Ramazanov B; Khusnutdinov R; Dunaev P; Khaibullina S; Lombardi V
Anticancer Drugs; 2016 Aug; 27(7):620-34. PubMed ID: 27129079
[TBL] [Abstract][Full Text] [Related]
12. Gastrointestinal stromal tumors: management of metastatic disease and emerging therapies.
Vadakara J; von Mehren M
Hematol Oncol Clin North Am; 2013 Oct; 27(5):905-20. PubMed ID: 24093167
[TBL] [Abstract][Full Text] [Related]
13. New therapeutic targets in soft tissue sarcoma.
Demicco EG; Maki RG; Lev DC; Lazar AJ
Adv Anat Pathol; 2012 May; 19(3):170-80. PubMed ID: 22498582
[TBL] [Abstract][Full Text] [Related]
14. Apatinib as targeted therapy for advanced bone and soft tissue sarcoma: a dilemma of reversing multidrug resistance while suffering drug resistance itself.
Yang QK; Chen T; Wang SQ; Zhang XJ; Yao ZX
Angiogenesis; 2020 Aug; 23(3):279-298. PubMed ID: 32333216
[TBL] [Abstract][Full Text] [Related]
15. Proteogenomics for the Study of Gastrointestinal Stromal Tumors.
Kondo T
Adv Exp Med Biol; 2016; 926():139-151. PubMed ID: 27686810
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of AKT-Signaling Sensitizes Soft Tissue Sarcomas (STS) and Gastrointestinal Stromal Tumors (GIST) to Doxorubicin via Targeting of Homology-Mediated DNA Repair.
Boichuk S; Bikinieva F; Nurgatina I; Dunaev P; Valeeva E; Aukhadieva A; Sabirov A; Galembikova A
Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33266502
[TBL] [Abstract][Full Text] [Related]
17. The benefit of using CT-perfusion imaging for reliable response monitoring in patients with gastrointestinal stromal tumor (GIST) undergoing treatment with novel targeted agents.
Betz M; Kopp HG; Spira D; Claussen CD; Horger M
Acta Radiol; 2013 Sep; 54(7):711-21. PubMed ID: 23761542
[TBL] [Abstract][Full Text] [Related]
18. Mutational Testing in Gastrointestinal Stromal Tumor.
Wang Y; Call J
Curr Cancer Drug Targets; 2019; 19(9):688-697. PubMed ID: 30914028
[TBL] [Abstract][Full Text] [Related]
19. Enhancer Domains in Gastrointestinal Stromal Tumor Regulate KIT Expression and Are Targetable by BET Bromodomain Inhibition.
Hemming ML; Lawlor MA; Andersen JL; Hagan T; Chipashvili O; Scott TG; Raut CP; Sicinska E; Armstrong SA; Demetri GD; Bradner JE
Cancer Res; 2019 Mar; 79(5):994-1009. PubMed ID: 30630822
[TBL] [Abstract][Full Text] [Related]
20. Fibroblast Growth Factor Receptor (FGFR) Signaling in GIST and Soft Tissue Sarcomas.
Napolitano A; Ostler AE; Jones RL; Huang PH
Cells; 2021 Jun; 10(6):. PubMed ID: 34204560
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
